Nektar Therapeutics is a leading biopharma company developing clinical stage products based upon its advanced polymer conjugate chemistry technology.
Based in San Francisco, Nektar Therapeutics partners its clinical stage products with big pharmaceutical companies who take them to market. Until now 9 products have reached the market through this strategy.
Nektar employs between 500 – 1000 employees and was established in 1990. The company is currently positioned at number 46 in the top 50 biotechnology list by revenue in 2014.
Nektar currently has over 20 clinical programs in development, many of which are in clinical trials and many of which are partnered up with big pharmaceutical companies. Nine products are focused to treat CNS/pain disorders, seven are oncology focused, three are indicated for infectious diseases, two for haemophilia and one for endocrine/metabolic disorders.
Figure 1 - Number of candidates partnered by big pharmaceutical companies
AstraZeneca partners alongside Nektar therapeutics in a worldwide focused agreement, that gives responsibility for development and commercialization of MOVANTIK™ - tablets for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Upon certain regulatory milestones Nektar is eligible to receive $235 million in aggregate payments.
Other candidates generating interest for the company is Amikacin inhale which is being developed in partnership with Bayer Healthcare. The product is a drug-device combination of specially formulated Amikacin inhale solution with Nektar’s pulmonary drug delivery system developed for the treatment of gram-negative pneumonia.
Well respected partner
Nektar is proud to be currently partnering with some of the word biggest pharmaceutical companies. It’s partnership deals range from joint discovery to co-development to licensing and royalty arrangements.
If you are interested in partnering you can contact the world class business team where you can speak to the Vice President, Business Development and the Executive directors who are based there.
Nektar Therapeutics is routinely present at a large number of partnering events throughout the year.
Partnering events are a great place to meet lots of potential partners face to face in a small amount of time.
Events with Nektar Therapeutics presence include but are not limited to:
- BIO International Convention and Business Forum
- BioEurope / BioEurope Spring
For a full list of forthcoming partnering events where you could meet with Nektar Therapeutics in person visit Current Partnering’s Event calendar.
Contacting Nektar Therapeutics for partnering
Nektar Therapeutics can be contacting in relation to partnering through a number of channels.
Here is a list of the most common channels:
Partnering events: face to face contact is generally considered the most effective form of contact. Partnering events not only allow face to face contact but also contact with multiple companies for the price of one flight and hotel reservation. This benefit makes partnering events the most cost effective method of making personal introductions as a start point for partnering discussions.
See Current Partnering’s event calendar for details of forthcoming events.
Direct contact: there are several sources of direct contact with Nektar's business development team
- Phone: Picking up the phone and speaking with an individual is the best form of non-face to face contact as it allows your name and voice to be remembered and associated with an opportunity.
- Email: Sending an email is another good way of making contact. Ideally, research the individual responsible for the therapy/technology area being targeted and get in touch. Email contact to a named individual.
- LinkedIn: Business to business contact is increasingly taking place via LinkedIn, the global online networking channel. Many of Nektar’s business development executives have LinkedIn profiles and can be found by viewing the company’s profile Nektar LinkedIn page here.
Opportunity submission form: the least favourable channel but worth using if you do not have access to the other channels mentioned above. Use the contact page to do this.
Our report provides more detailed insight into the details of each deal. See: Partnering Agreements with Nektar Therapeutics 2009-2014
Nektar Therapeutics partnering at Current Agreements
Full details on each deal can be found at CurrentAgreements (subscription required)
Or purchase report: Partnering Agreements with Nektar Therapeutics 2009-2014
No M&A activity for Nektar Therapeutics
Available reports from Current Partnering
Available resources for deal coverage for Nektar Therapeutics
Read: more on Nektar Therapeutics company profile, recent partnering, M&A and financing news and articles
View: CP Insight’s Partnering Scorecard – view top life science partnering deals by value
View: CP Insight’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk